title: Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
authors: Department of Gynaecology and Obstetrics, National Center for Tumour Diseases, University of Heidelberg, 69115 Heidelberg, Germany.
authors: Sarah
authors: S
authors: Schott
authors: Markus
authors: M
authors: Wallwiener
authors: Beate
authors: B
authors: Kootz
authors: Harald
authors: H
authors: Seeger
authors: Tanja
authors: T
authors: Fehm
authors: Hans
authors: H
authors: Neubauer
references: Med Biol. 1984;62(6):338-43
references: 6543460
references: Clin Pharmacokinet. 2003;42(15):1319-30
references: 14674786
references: Bone. 2006 May;38(5):613-6
references: 16504613
references: Anticancer Drugs. 2005 Oct;16(9):969-76
references: 16162973
references: Urol Res. 1999;27(1):17-22
references: 10092149
references: Cancer Treat Rev. 1990 Sep;17(2-3):253-9
references: 2272041
references: Am J Obstet Gynecol. 1991 Aug;165(2):245-55
references: 1872324
references: Anticancer Drugs. 1998 Jan;9(1):51-7
references: 9491792
references: Cancer Res. 1995 Nov 15;55(22):5276-82
references: 7585588
references: BMC Cancer. 2003 Jul 03;3:19
references: 12841853
references: Ann Oncol. 2008 Mar;19(3):420-32
references: 17906299
references: Anticancer Drugs. 2008 Apr;19(4):391-9
references: 18454049
references: Support Care Cancer. 2006 May;14(5):408-18
references: 16450087
references: Bone. 2010 Jul;47(1):12-22
references: 20233612
references: Gynecol Oncol. 2000 May;77(2):258-63
references: 10785475
references: Urol Res. 1992;20(3):215-7
references: 1615583
references: Gynecol Oncol. 1988 Sep;31(1):191-204
references: 3410347
references: Breast. 2007 Dec;16 Suppl 3:S16-20
references: 18032044
references: Invest New Drugs. 2011 Jun;29(3):506-13
references: 19997962
references: Anticancer Res. 2008 Mar-Apr;28(2A):949-55
references: 18507041
references: Oncologist. 2004;9 Suppl 4:3-13
references: 15459425